Armata Pharmaceuticals Inc (ARMP)

$2.94 -0.02 (-0.68%)
Market Cap 106.52M
Revenue (ttm) 5.17M
Net Income (ttm) -18.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -365.96%
Debt to Equity Ratio -1.62
Volume 6,000
Avg Vol 12,788
Day's Range N/A - N/A
Shares Out 36.23M
Stochastic %K 73%
Beta 1.09
Analysts Sell
Price Target $9.00

Company Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 665 2928
Fax: 310 665 2963
Address:
5005 McConnell Avenue, Los Angeles, United States
Trapped
Trapped Sep. 4 at 12:11 PM
$ARMP stock has been rising for a few months now. my guess FDA trials are positive.
0 · Reply
History101
History101 Sep. 3 at 8:12 PM
$ARMP huge jump today & so far after hours, i wonder what's happening
0 · Reply
History101
History101 Sep. 3 at 8:11 PM
$ARMP 7,988 watching 9/3/2025
0 · Reply
DMZ66
DMZ66 Aug. 25 at 4:48 PM
$ARMP cytophage technologies inc https://cytophage.com/news/cytophage-secures-health-canada-validation-for-ovaphage-and-phagefend-products-for-use-in-food-safety/ undervalued major sleeper for those interested.
0 · Reply
LiquidityCraft
LiquidityCraft Aug. 23 at 5:59 AM
$ARMP Armata Pharmaceuticals is a clinical stage bacteriophage therapy company with high risk
0 · Reply
FearAndFib
FearAndFib Aug. 22 at 4:41 AM
$ARMP Armata Pharmaceuticals is a clinical stage biotech developing bacteriophage therapies highly speculative with funding needs and regulatory hurdles
0 · Reply
Trapped
Trapped Aug. 4 at 7:26 PM
$ARMP approaching annual high pps. things are happening!!!
0 · Reply
DMZ66
DMZ66 Jul. 24 at 11:32 PM
$ARMP keep your eye on Cytophage technologies inc many irons in the fire. CYTO (tsx exchange) major sleeper!
0 · Reply
Trapped
Trapped Jul. 16 at 3:45 PM
$ARMP i hope you all grab some before a PR. don’t chase
0 · Reply
HexBinance
HexBinance Jul. 14 at 8:42 PM
$ARMP load the f***ing boat.
0 · Reply
Latest News on ARMP
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Sep 8, 2025, 7:00 AM EDT - 5 days ago

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:00 AM EDT - 9 days ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Aug 12, 2025, 4:05 PM EDT - 4 weeks ago

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

May 19, 2025, 7:00 AM EDT - 4 months ago

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 4 months ago

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

May 1, 2025, 7:00 AM EDT - 4 months ago

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Mar 20, 2025, 5:56 PM EDT - 6 months ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Mar 12, 2025, 5:08 PM EDT - 6 months ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

INVA

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Mar 11, 2025, 7:00 AM EDT - 6 months ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Dec 19, 2024, 7:00 AM EST - 9 months ago

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Nov 19, 2024, 7:00 AM EST - 10 months ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Nov 13, 2024, 4:05 PM EST - 10 months ago

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

Nov 12, 2024, 7:00 AM EST - 10 months ago

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

Armata Pharmaceuticals Announces Structural Biology Publication

Oct 30, 2024, 7:00 AM EDT - 11 months ago

Armata Pharmaceuticals Announces Structural Biology Publication

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Aug 26, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Aug 15, 2024, 4:45 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

Jul 10, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

May 7, 2024, 4:01 PM EDT - 1 year ago

Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Mar 4, 2024, 4:01 PM EST - 1 year ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

INVA

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Feb 21, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Nov 14, 2023, 4:00 PM EST - 1 year ago

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

May 31, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

May 11, 2023, 4:05 PM EDT - 2 years ago

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

Mar 16, 2023, 4:10 PM EDT - 2 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

Mar 6, 2023, 6:00 AM EST - 2 years ago

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

Jan 10, 2023, 4:05 PM EST - 2 years ago

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

INVA

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Dec 22, 2022, 8:00 AM EST - 2 years ago

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

Nov 28, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

Nov 9, 2022, 4:15 PM EST - 3 years ago

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

Aug 1, 2022, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus

May 23, 2022, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus

Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update

May 12, 2022, 4:17 PM EDT - 3 years ago

Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva

Mar 31, 2022, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva

INVA

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update

Mar 17, 2022, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update

HATCHspaces®, NexCore Group, and Nuveen Real Estate to Convert 56,300 SF Industrial Building to Biomanufacturing in West Los Angeles

Mar 9, 2022, 1:00 PM EST - 3 years ago

HATCHspaces®, NexCore Group, and Nuveen Real Estate to Convert 56,300 SF Industrial Building to Biomanufacturing in West Los Angeles

Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis

Feb 22, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis

Armata Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Feb 17, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development

Feb 9, 2022, 4:16 PM EST - 3 years ago

Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development

INVA

Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs

Jan 5, 2022, 8:00 AM EST - 4 years ago

Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs

Trapped
Trapped Sep. 4 at 12:11 PM
$ARMP stock has been rising for a few months now. my guess FDA trials are positive.
0 · Reply
History101
History101 Sep. 3 at 8:12 PM
$ARMP huge jump today & so far after hours, i wonder what's happening
0 · Reply
History101
History101 Sep. 3 at 8:11 PM
$ARMP 7,988 watching 9/3/2025
0 · Reply
DMZ66
DMZ66 Aug. 25 at 4:48 PM
$ARMP cytophage technologies inc https://cytophage.com/news/cytophage-secures-health-canada-validation-for-ovaphage-and-phagefend-products-for-use-in-food-safety/ undervalued major sleeper for those interested.
0 · Reply
LiquidityCraft
LiquidityCraft Aug. 23 at 5:59 AM
$ARMP Armata Pharmaceuticals is a clinical stage bacteriophage therapy company with high risk
0 · Reply
FearAndFib
FearAndFib Aug. 22 at 4:41 AM
$ARMP Armata Pharmaceuticals is a clinical stage biotech developing bacteriophage therapies highly speculative with funding needs and regulatory hurdles
0 · Reply
Trapped
Trapped Aug. 4 at 7:26 PM
$ARMP approaching annual high pps. things are happening!!!
0 · Reply
DMZ66
DMZ66 Jul. 24 at 11:32 PM
$ARMP keep your eye on Cytophage technologies inc many irons in the fire. CYTO (tsx exchange) major sleeper!
0 · Reply
Trapped
Trapped Jul. 16 at 3:45 PM
$ARMP i hope you all grab some before a PR. don’t chase
0 · Reply
HexBinance
HexBinance Jul. 14 at 8:42 PM
$ARMP load the f***ing boat.
0 · Reply
HexBinance
HexBinance Jul. 10 at 1:32 PM
$ARMP will blow on even mildly good news. Dare i say squeeze potental?
0 · Reply
Trapped
Trapped Jul. 10 at 1:07 PM
$ARMP next step $3
0 · Reply
Trapped
Trapped Jul. 3 at 4:21 PM
$ARMP going to pop soon!!!!!
0 · Reply
SiRichard83
SiRichard83 Jun. 15 at 7:41 PM
$ARMP 8023 watchers
0 · Reply
AmineF05
AmineF05 May. 29 at 5:54 PM
$ARMP
0 · Reply
Pumpernotgonnalie
Pumpernotgonnalie May. 29 at 5:24 PM
$ARMP slow and steady up we go
0 · Reply
Sw1ngb0t
Sw1ngb0t May. 28 at 8:30 PM
$SGBX $EDBL $ARMP $PMAX $FAAS
0 · Reply
jbrkb
jbrkb May. 28 at 4:40 PM
$ARMP chart
1 · Reply
Trapped
Trapped May. 28 at 12:04 PM
$ARMP this stock should be $4 by now. who’s holding it back?
0 · Reply
Sw1ngb0t
Sw1ngb0t May. 28 at 2:43 AM
$FAAS $ARMP $LVWR $IMNN
0 · Reply
SiRichard83
SiRichard83 May. 26 at 10:39 AM
$ARMP 8k followers
0 · Reply
Trapped
Trapped May. 23 at 4:30 PM
$ARMP CEO has the connections to make this forward … fast track approval
0 · Reply